PaxVax names new CEO
This article was originally published in Scrip
PaxVax, a specialty vaccine company focused on travel and biodefense, has appointed Nima Farzan CEO and president of the company. In this role, he will assume overall responsibility for PaxVax, including management of all R&D, manufacturing and commercial operations globally. Kenneth Kelley, co-founder and former CEO, will continue to serve PaxVax as a director on the company's board of directors and as an advanced leadership initiative fellow at Harvard University focused on related global health issues.